Chapters

Transcript

Video

What’s your rationale for duvelisib dosing in: (1) bridging to allogeneic transplant, (2) achieving CR in R/R PTCL-TFH, and (3) palliative care?


Created by

CMEducation Resources iQ&A PTCL Hematology-Oncology Intelligence Zone

Presenter

Christina Poh, MD

Christina Poh, MD

Physician, Fred Hutchinson Cancer CenterAssistant Professor, Division of Hematology and OncologyUniversity of Washington School of MedicineSeattle, Washington